IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Clinical Advances in Hematology and Oncology

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on September 3, 2024

Impact Score

2023-2024

0.42

h-Index

2023-2024

 43

Rank

2023-2024

 16969

SJR

2023-2024

 0.264

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Clinical Advances in Hematology and Oncology
Abbreviation Clin. Adv. Hematol. Oncol.
Publication Type Journal
Subject Area, Categories, Scope Medicine (miscellaneous) (Q3); Oncology (Q3); Hematology (Q4)
h-index 43
Overall Rank/Ranking 16969
SCImago Journal Rank (SJR) 0.264
Impact Score 0.42
Publisher Millennium Medical Publishing, Inc.
Country United States
ISSN 15430790
Best Quartile Q3
Coverage History 2003-2023




About Clinical Advances in Hematology and Oncology


Clinical Advances in Hematology and Oncology is a journal covering the technologies/fields/categories related to Medicine (miscellaneous) (Q3); Oncology (Q3); Hematology (Q4). It is published by Millennium Medical Publishing, Inc.. The overall rank of Clinical Advances in Hematology and Oncology is 16969. According to SCImago Journal Rank (SJR), this journal is ranked 0.264. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 43. The best quartile for this journal is Q3.

The ISSN of Clinical Advances in Hematology and Oncology journal is 15430790. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Clinical Advances in Hematology and Oncology is cited by a total of 209 articles during the last 3 years (Preceding 2023).


Clinical Advances in Hematology and Oncology Impact IF 2023-2024


The Impact IF 2023 of Clinical Advances in Hematology and Oncology is 0.42, which is computed in 2024 as per its definition. Clinical Advances in Hematology and Oncology IF is increased by a factor of 0.01 and approximate percentage change is 2.44% when compared to preceding year 2022, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Clinical Advances in Hematology and Oncology Impact IF 2024 Prediction


Impact IF 2023 of Clinical Advances in Hematology and Oncology is 0.42. If the same upward trend persists, Impact IF may rise in 2024 as well.


Impact IF Trend


Year wise Impact IF of Clinical Advances in Hematology and Oncology. Based on Scopus data.


Year Impact IF
2023/2024 Coming Soon
2023 0.42
2022 0.41
2021 0.52
2020 0.69
2019 0.49
2018 0.63
2017 0.62
2016 0.57
2015 0.55
2014 0.45

Clinical Advances in Hematology and Oncology h-index


  Table Setting

Clinical Advances in Hematology and Oncology has an h-index of 43. It means 43 articles of this journal have more than 43 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Clinical Advances in Hematology and Oncology ISSN


The ISSN of Clinical Advances in Hematology and Oncology is 15430790. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Clinical Advances in Hematology and Oncology Rank and SCImago Journal Rank (SJR)


The overall rank of Clinical Advances in Hematology and Oncology is 16969. According to SCImago Journal Rank (SJR), this journal is ranked 0.264. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Clinical Advances in Hematology and Oncology by Year


Year SJR
2023/2024 Coming Soon
2023 0.264
2022 0.337
2021 0.323
2020 0.414
2019 0.462
2018 0.588
2017 0.595
2016 0.376
2015 0.361
2014 0.289

Ranking of Clinical Advances in Hematology and Oncology by Year


Year Ranking
2023/2024 Coming Soon
2023 16969
2022 14041
2021 14100
2020 11772
2019 10506
2018 8217
2017 7919
2016 11551
2015 11771
2014 13374

Clinical Advances in Hematology and Oncology Publisher


Table Setting

Clinical Advances in Hematology and Oncology is published by Millennium Medical Publishing, Inc.. It's publishing house is located in United States. Coverage history of this journal is as following: 2003-2023. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Clinical Advances in Hematology and Oncology is Clin. Adv. Hematol. Oncol.. This abbreviation ('Clin. Adv. Hematol. Oncol.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Clinical Advances in Hematology and Oncology


If your research field is/are related to Medicine (miscellaneous) (Q3); Oncology (Q3); Hematology (Q4), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Clinical Advances in Hematology and Oncology?

Clinical Advances in Hematology and Oncology latest impact IF is 0.42. It's evaluated in the year 2023. The highest and the lowest impact IF or impact score of this journal are 0.69 (2020) and 0.41 (2022), respectively, in the last 10 years. Moreover, its average IS is 0.54 in the previous 10 years.


What's the SCImago Journal Rank (SJR) of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology has an SJR (SCImago Journal Rank) of 0.264, according to the latest data. It is computed in the year 2024. In the past 10 years, this journal has recorded a range of SJR, with the highest being 0.595 in 2017 and the lowest being 0.264 in 2023. Furthermore, the average SJR of the Clinical Advances in Hematology and Oncology over the previous 10-year period stands at 0.54.


What's the latest h-index of the Clinical Advances in Hematology and Oncology?

The latest h-index of the Clinical Advances in Hematology and Oncology is 43.


Who's the publisher of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology is published by the Millennium Medical Publishing, Inc., with its country of publication being the United States.


What's the current ranking of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology is currently ranked 16969 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 10 years, this journal has experienced varying rankings, reaching its highest position of 7919 in 2017 and its lowest position of 16969 in 2023.


What's the abbreviation or short name for the Clinical Advances in Hematology and Oncology?

The standard ISO4 abbreviation for the Clinical Advances in Hematology and Oncology is Clin. Adv. Hematol. Oncol..


Is the "Clinical Advances in Hematology and Oncology" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Clinical Advances in Hematology and Oncology is classified as a journal that the Millennium Medical Publishing, Inc. publishes.


What's the scope or major areas of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology encompasses the following areas:

  • Medicine (miscellaneous)
  • Oncology
  • Hematology

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology is assigned the following International Standard Serial Numbers (ISSN): 15430790.


What's the best quartile of the Clinical Advances in Hematology and Oncology?

The best quartile for the Clinical Advances in Hematology and Oncology is Q3 (2023).


What's the coverage history of the Clinical Advances in Hematology and Oncology?

The Clinical Advances in Hematology and Oncology coverage history can be summarized as follows: 2003-2023.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Zeitschrift fur Germanistische Linguistik journal 14988 Walter de Gruyter GmbH 16 0.40
Proceedings of the International Symposium on Power Semiconductor Devices and ICs conference and proceedings 7015 49 2.14
Archives of Phytopathology and Plant Protection journal 15268 Taylor and Francis Ltd. 33 1.39
Abacus journal 5997 Wiley-Blackwell Publishing Ltd 53 2.75
Socialism and Democracy journal 25103 Taylor and Francis Ltd. 18 0.12
Sex Education journal 7722 Routledge 45 2.66
European Surgery - Acta Chirurgica Austriaca journal 18870 Springer Medizin 24 0.60
International Conference on Architectural Support for Programming Languages and Operating Systems - ASPLOS conference and proceedings 678 Association for Computing Machinery (ACM) 106 7.58
Genes and Nutrition journal 5793 BioMed Central Ltd 65 3.42
Archiv fur Geflugelkunde journal 28770 Verlag Eugen Ulmer 30 0.00

Check complete list




Year wise Impact Score (IS) of Clinical Advances in Hematology and Oncology

Impact Score Table

Year Impact Score (IS)
2024/2025 Coming Soon
2023 0.42
2022 0.41
2021 0.52
2020 0.69
2019 0.49
2018 0.63
2017 0.62
2016 0.57
2015 0.55
2014 0.45



Top Journals/Conferences in Medicine (miscellaneous)

Nature Reviews Drug Discovery
Nature Publishing Group | United Kingdom

New England Journal of Medicine
Massachussetts Medical Society | United States

Nature Medicine
Nature Research | United Kingdom

Current Protocols in Bioinformatics
John Wiley & Sons Inc. | United States

MMWR supplements
Epidemiology Program Office | United States

Nature Reviews Immunology
Nature Publishing Group | United Kingdom

MMWR Recommendations and Reports
Centers for Disease Control and Prevention (CDC) | United States

Annals of Oncology
Elsevier Ltd | United Kingdom

Morbidity and Mortality Weekly Report
Department of Health and Human Services | United States

Nature Reviews Methods Primers
Springer Nature | United States

See All

Top Journals/Conferences in Oncology

Ca-A Cancer Journal for Clinicians
Wiley-Blackwell | United States

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Nature Reviews Clinical Oncology
Nature Publishing Group | United Kingdom

Cancer Cell
Cell Press | United States

Annals of Oncology
Elsevier Ltd | United Kingdom

Lancet Oncology, The
Elsevier Ltd | United Kingdom

Nature Cancer
Nature Research | United States

Journal of Clinical Oncology
Lippincott Williams and Wilkins Ltd. | United States

Molecular Cancer
BioMed Central Ltd | United Kingdom

Journal of Thoracic Oncology
Elsevier Inc. | United States

See All

Top Journals/Conferences in Hematology

Ca-A Cancer Journal for Clinicians
Wiley-Blackwell | United States

Annals of Oncology
Elsevier Ltd | United Kingdom

Journal of Hematology and Oncology
BioMed Central Ltd | United Kingdom

Blood
Elsevier B.V. | United States

Blood cancer discovery
NLM (Medline) | United States

Blood Cancer Journal
Nature Publishing Group | United States

Lancet Haematology,The
Lancet Publishing Group | United Kingdom

Leukemia
Nature Publishing Group | United Kingdom

Blood advances
American Society of Hematology | United States

Journal of the National Cancer Center
| China

See All